Avacta Group provide clarification regarding Medusa 19 antibody test

lab

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, issues clarification following information appearing on the Medusa 19 web site regarding a SARS-CoV-2 antibody test on Friday, 14 August 2020.

Avacta is not involved with Medusa 19’s development of the antibody test.  Performance figures appearing on Medusa 19’s web site on Friday, 14 August 2020 relate to this antibody test and do not relate to Avacta’s rapid SARS-CoV-2 antigen test.

AVCT will update the market on continued progress and on the performance of its antigen test when appropriate.

Find more news, interviews, share price & company profile here for:
Avacta Group Plc

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit
Find more news, interviews, share price & company profile here for:
Avacta Group Plc

AIM All Share Index